Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 3;11(12):1750.
doi: 10.3390/antibiotics11121750.

Potential Nitrogen-Based Heterocyclic Compounds for Treating Infectious Diseases: A Literature Review

Affiliations
Review

Potential Nitrogen-Based Heterocyclic Compounds for Treating Infectious Diseases: A Literature Review

Mohammad Aatif et al. Antibiotics (Basel). .

Abstract

Heterocyclic compounds are considered as one of the major and most diverse family of organic compounds. Nowadays, the demand for these compounds is increasing day-by-day due to their enormous synthetic and biological applications. These heterocyclic compounds have unique antibacterial activity against various Gram-positive and Gram-negative bacterial strains. This review covers the antibacterial activity of different heterocyclic compounds with nitrogen moiety. Some of the derivatives of these compounds show excellent antibacterial activity, while others show reasonable activity against bacterial strains. This review paper aims to bring and discuss the detailed information on the antibacterial activity of various nitrogen-based heterocyclic compounds. It will be helpful for the future evolution of diseases to synthesize new and effective drug molecules.

Keywords: heterocyclic compound; in-vitro studies; infectious disease; medicinal chemistry; organic synthesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Literature survey of antibacterial activity of nitrogen-based heterocyclic compounds.
Scheme 1
Scheme 1
Synthetic route of pyrrole and its derivatives (427).
Scheme 2
Scheme 2
Synthetic route for the synthesis of pyrrole[3,4-b]quinolin-2(3H)-yl)bezamide derivatives (3741).
Scheme 3
Scheme 3
Synthetic route of compound 44.
Scheme 4
Scheme 4
Synthesis of pyrrole from 1,4-dicarbonyls.
Scheme 5
Scheme 5
Synthesis of bis-pyrrole derivatives.
Scheme 6
Scheme 6
Synthesis of 2H-chromene fused pyrrole derivatives (6476).
Scheme 7
Scheme 7
Synthetic route of pyrimidine from aromatic aldehyde (8290).
Scheme 8
Scheme 8
Synthesis of pyrimidine derivatives of 1,5-benzodiazepine from benzoylacetonitrile.
Scheme 9
Scheme 9
Synthesis of new benzo[5,6]chromeno[2,3-d]pyrimidines (100106).
Scheme 10
Scheme 10
Synthesis of pyrimidine using acetamidine and isonicotinamidine.
Scheme 11
Scheme 11
Synthesis of bis-pyrimidines (126134).
Scheme 12
Scheme 12
Synthesis of thieno[2,3-d]pyrimidine-alkyne.
Scheme 13
Scheme 13
Synthesis of 3,4-dihydro-5-(5-mercapto-4H-1,2,4-triazol-3-yl)-6-methyl-4-phenyl pyrimidin-2(1H)-one (161180).
Scheme 14
Scheme 14
(Thiazol-2-yl)pyrazol-5-amines from pyrazolylthioureas and ω-bromoacetophenones.
Scheme 15
Scheme 15
Synthetic route of compounds (192209).
Scheme 16
Scheme 16
Synthetic routes of various thiazoles.
Scheme 17
Scheme 17
Synthetic routes of thiazole.
Scheme 18
Scheme 18
Synthesis of thiazole from thiourea (253256).
Scheme 19
Scheme 19
Total synthesis of 4-thiazolylpyrazoles.
Scheme 20
Scheme 20
Synthetic routes of substituted thiazole.
Scheme 21
Scheme 21
The synthetic route to thiazole having pleuromutilin moiety.
Scheme 22
Scheme 22
Synthesis of di-substituted pyridine (287306).
Scheme 23
Scheme 23
Synthesis of 6,8-dichloro-2-methylimidazo[1,2-a]pyridinyl-pyridine hybrids.
Scheme 24
Scheme 24
Synthesis of fused heterocyclic compounds (Pyridine).
Scheme 25
Scheme 25
Synthetic route of pyridine from urea derivatives.
Scheme 26
Scheme 26
Synthesis of 3-amino-6-(trifluoromethyl)-1H-pyrazolo[3,4-b] pyridine-5-carboxylate.
Scheme 27
Scheme 27
Synthesis of formyl pyridine. a = AcONH4/EtOH.
Scheme 28
Scheme 28
Synthesis of arylmethylene-isoxazol-5(4H)-one derivatives. a = LiBr/EtOH.
Scheme 29
Scheme 29
Synthetic route of oxazole from hydroxyl aniline. a = CS2/KOH/Reflux, b = Propargylbromide/K2CO3/m-CPBA/ArN3/CuI/[Bmim]PF6.
Scheme 30
Scheme 30
Synthesis of 1,2-oxazoles 364369.
Scheme 31
Scheme 31
Synthetic route of compounds 374376.
Scheme 32
Scheme 32
Synthetic route of oxazole (379).
Scheme 33
Scheme 33
Synthetic route of compounds (383385).
Scheme 34
Scheme 34
Synthesis of benzothiazole and benzoxazole linked 1,4-disubstituted 1,2,3-triazoles.
Scheme 35
Scheme 35
Synthesis of 3-(2-aminooxazol-5-yl)-2H-chromen-2-one derivatives (414426).
Scheme 36
Scheme 36
Synthesis of sulfonamide bearing thiazolidinone (430445).
Scheme 37
Scheme 37
Synthesis of substituted 2-phenyl-3-(2-(trifluoromethyl)-1H-benzimidazol-6-yl)thiazolidin-4-ones.
Scheme 38
Scheme 38
Synthesis of 2-(9-chloro-2,3-dimethyl- 6,7-dihydro-5H-benzo[7] annulen-8-yl)-3-(3-oxo-3-[piperazin-1-yl]propyl)thiazolidin-4-one derivatives.
Scheme 39
Scheme 39
Synthetic pathways for compounds (477486).
Scheme 40
Scheme 40
Synthesis of thiazolidinone from benzylalcohol.
Scheme 41
Scheme 41
Synthesis of thiazolidinone from benzoic acid (497506).
Scheme 42
Scheme 42
Synthesis of imidazole from diamine.
Scheme 43
Scheme 43
Synthesis of imidazole-based 1,4-naphthoquinone.
Scheme 44
Scheme 44
Synthesis of 5-methyl-2-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)phenol, 2-[2-(furan-2-yl)-4,5-diphenyl-1H-imidazol-1-yl]-5- methylphenol and 5-methyl-2-(2, 4, 5-triphenyl-1H-imidazole-1-yl) phenol.

References

    1. Cheddie A., Shintre S.A., Bantho A., Mocktar C., Koorbanally N.A. Synthesis and antibacterial activity of a series of 2-trifluoromethylbenzimidazole-thiazolidinone derivatives. J. Heterocycl. Chem. 2020;57:299–307. doi: 10.1002/jhet.3777. - DOI
    1. Hassoun A., Linden P.K., Friedman B. Incidence, prevalence, and management of MRSA bacteremia across patient populations—A review of recent developments in MRSA management and treatment. Crit. Care. 2017;21:211. doi: 10.1186/s13054-017-1801-3. - DOI - PMC - PubMed
    1. Campbell I.B., Macdonald S.J., Procopiou P.A. Medicinal chemistry in drug discovery in big pharma: Past, present and future. Drug Discov. Today. 2018;23:219–234. doi: 10.1016/j.drudis.2017.10.007. - DOI - PubMed
    1. Sreedevi R., Saranya S., Anilkumar G. Recent Trends in the Silver-Catalyzed Synthesis of Nitrogen Heterocycles. Adv. Synth. Catal. 2019;361:4625–4644. doi: 10.1002/adsc.201900599. - DOI
    1. Ghaemi M., Pordel M. Isoxazolo [4, 3-e] indazole as a new heterocyclic system: Design, synthesis, spectroscopic characterization, and antibacterial activity. Chem. Heterocycl. Compd. 2016;52:52–57. doi: 10.1007/s10593-016-1833-7. - DOI

LinkOut - more resources